



NIH funding opportunities



Faculty of Medicine and Health Sciences: Research Development and Support

15 Jun 2020 (#29)

[Click on blue [hyperlink](#) for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov or www.sun.ac.za/RDSfunding (current & archive).

Confirm your intent to apply ASAP, but not later than 60 days before the submission date.

Tygerberg Campus: cdevries@sun.ac.za • Stellenbosch Campus lizelk@sun.ac.za

Important Notice

- [COVID-19 information for NIH grant applicants and grant recipients](#), including NIH funding opportunities specific to COVID-19 from the NIH Office of Extramural Research (OER)
- [Coronavirus news, funding and resources for global health researchers](#) compiled by Fogarty
- [NOT-OD-20-123 Special Exception to the NIH/AHRQ/NIOSH Post-Submission Material Policy during the COVID-19 Pandemic](#). For applications submitted for the January 2021 council (beginning with applications submitted for the May 25, 2020 due date for Fall 2020 review meetings), the NIH, AHRQ, and NIOSH will accept a one-page update with preliminary data as post-submission materials for applications submitted under all activity codes, ONLY if the Funding Opportunity Announcement (FOA) used for submission allowed preliminary data in the application.
- [NOT-GM-20-036 Notice of Joint DMS/NIGMS Initiative to Support Research at the Interface of the Biological and Mathematical Sciences](#). The National Institute of General Medical Sciences (NIGMS) and the Division of Mathematical Sciences (DMS) in the Directorate for Mathematical and Physical Sciences (MPS) at the National Science Foundation (NSF) plan to support fundamental research in mathematics and statistics necessary to answer questions in the biological and biomedical sciences. Both agencies recognize the need to promote research at the interface between mathematical and life sciences. This program is designed to encourage new collaborations, as well as to support innovative activities by existing teams. NIGMS and DMS anticipate making 15 to 25 awards totalling up to \$5 million per year.
- [NOT-AI-20-044 Notice of Special Interest \(NOSI\): NIAID Priorities for Biomedical Knowledgebase & Repositories](#) The purpose of this NOSI is to communicate NIAID's special interest in potential applications under the Biomedical Data Repository (PAR-20-089) and Knowledgebase (PAR-20-097) FOAs, focused on the establishment of new, or continued development/renewal of existing repositories and knowledgebase that are of high-value relevance to the immune-mediated and infectious disease research community.
- [NOT-DA-20-060 Notice of Special Interest \(NOSI\): Role of Astrocytes and Astrocytic Networks in Drug Abuse](#). The purpose of this Notice is to inform potential applicants of NIDA's interest in research project grant submissions that examine the effects of drugs of abuse on the function and functional roles of astrocytes, the structural connectivity of astrocytic networks, the generation, processing and spatiotemporal control of astrocytic activity within these networks, and the consequent effects of changes in astrocyte activity due to drugs of abuse on neuronal structure and function.
- [NOT-HL-20-796 Notice of Special Interest \(NOSI\): Bold New Bioengineering Research for Heart, Lung, Blood and Sleep Disorders and Diseases \(Reissue\)](#). The purpose of this Notice of Special Interest is to inform potential applicants to the National Heart, Lung and Blood Institute (NHLBI) of an area of special interest in exploring bold, new bioengineering approaches or concepts, including computationally-efficient methods, that are important to a substantive heart, lung, blood or sleep area, and in supporting the early phases of these innovative bioengineering projects which are, in turn, expected to transition into research to translate them into practice, technologies, or commercial products.

1. Pilot Projects Increasing the Impact of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (PI2 CARBON) (R03 Clinical Trials Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-228](#)

Type: R03

Application Due Date: Oct 1, 2020; June 1, 2021; February 1, 2022; September 30, 2022. Aids dates: Oct 15, 2020; June 15, 2021; February 15, 2022; October 14, 2022. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to support collaborative pilot research projects focused on potential effects relevant to human health of chemically complex natural products and/or the causal, molecular mechanisms underlying such effects. A critical element of each proposed project must be collaboration with one or more of the NIH Centers for Advancing Research on Botanicals and Other Natural Products (CARBON). More specifically, letters of support describing collaboration with one or more of the U19 Botanical Dietary Supplements Research Centers awarded pursuant to [RFA OD-19-001](#) by July, 2020, must be included at the time of submission. Each proposed pilot project must, with agreement of its collaborating Center(s), leverage products used in those Centers to extend understanding of their biological effects, or of their causal, molecular mechanisms of action, or increase understanding of other chemically complex natural products through use of methods developed and used in the Centers. Research approaches may range from bench through *in vitro* and non-human animal models to, where feasible and appropriate, obtaining additional feasibility or outcome information from the clinical trials being performed by the CARBON awardees, either through inclusion of additional measures or through secondary analysis of data or specimens.

Budget: Application budgets are limited to \$50,000 in direct costs per year. The scope of the proposed project should determine the project period. The maximum project period is 2 years.

2. Global Infectious Disease Research Training Program (D43 Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-229](#)

Type: D43

Application Due Date: August 14, 2020, August 3, 2021, August 3, 2022 Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages joint applications for the Global Infectious Disease (GID) Research Training programs from U.S. and low- and middle-income country (LMIC) institutions. The application should propose a collaborative training program that will strengthen the capacity of a LMIC institution to conduct infectious disease research not including HIV/AIDS. FIC will support research-training programs that focus on major endemic or life-threatening emerging infectious diseases, neglected tropical diseases, infections that frequently occur as co-infections in HIV infected individuals or infections associated with non-communicable disease conditions of public health importance in LMICs. Training related to prevention, treatment or public health approaches to any technical area of basic, epidemiology, clinical, behavioral or social science health research may be supported. Research Training programs should incorporate didactic, mentored research and professional development skills components to prepare individuals for careers that will have significant impact on the priority health research needs of LMICs. This Funding Opportunity Announcement (FOA) allows support of trainees as the lead investigator of an independent clinical trial; or a separate ancillary clinical trial or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and professional development.

Budget: Application budgets are limited to \$230,000 per year for new awards and \$276,000 per year for renewal awards (total direct costs). The maximum project period allowed is 5 years.

3. Center for Inherited Disease Research (CIDR) High Throughput Sequencing and Genotyping Resource Access (X01 Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date

Hyperlink: [PAR-20-230](#)

Type: X01

Application Due Date: Applications are accepted by continuous receipt. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The Center for Inherited Disease Research (CIDR) high-throughput genotyping, sequencing and supporting statistical genetics services are designed to aid the identification of genes or genetic modifications that contribute to human health and disease or to enhance existing collections of well-phenotyped specimens by the addition of genotype or next-generation sequence data. The laboratory specializes in genomic services that cannot be efficiently carried out in individual investigator laboratories. CIDR provides the most up-to-date platforms, services and statistical genetic support. This is an NIH-wide initiative that is managed by NHGRI. Information about current services offered can be accessed via: <http://www.cidr.jhmi.edu>.

Budget: Not Applicable: there is no budget associated with X01 Resource Access Awards. The maximum project period is 5 years.

Research Development and Support Division (RDSD),
Faculty of Medicine and Health Sciences, Stellenbosch University
5th Floor, Teaching Block, Tygerberg Campus.
Enquiries: *Christa*
e: cdevries@sun.ac.za | t: +27 21 938 9838

Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Stellenbosch University
2038 Wilcocks Building, Ryneveld Street
Enquiries: *Lizél*
e: lizelk@sun.ac.za | t: +27 21 808 2105